Review
Oncology
Vladimir Laletin, Pierre-Louis Bernard, Cathy Costa da Silva, Geoffrey Guittard, Jacques A. Nunes
Summary: Immunotherapy strategies targeting T cells have been effective in treating cancer by blocking immune checkpoints. However, many patients do not respond to these treatments, so alternative approaches are needed. In addition to membrane-associated inhibitory molecules, intracellular immune checkpoints (iICPs) may also downregulate TCR signaling and inhibiting them shows promise for future cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Fisheries
Kete Ai, Jie Yan, Kang Li, Cheng Li, Yu Zhang, Wei Liang, Jiaqi Li, Xiumei Wei, Jialong Yang
Summary: Using a Nile tilapia model, this study investigated the regulatory role of Akt1 in the adaptive immunity of teleost fish, demonstrating Akt1's involvement in primary adaptive immune response through promoting lymphocyte activation and proliferation via mTORC1 signaling.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY
(2021)
Review
Immunology
Ellen McAllister, Julia Jellusova
Summary: BAFF is a crucial cytokine that not only maintains B cell homeostasis but also drives a metabolic program in B cells, increasing their capacity to divide. Components of the signaling cascades initiated by BAFF have roles in metabolic reprogramming, and further exploration of BAFF signaling in B cell metabolism could help identify metabolic vulnerabilities in hyperactive B cells in autoimmunity.
CURRENT OPINION IN IMMUNOLOGY
(2021)
Article
Oncology
Pierre-Louis Bernard, Rebecca Delconte, Sonia Pastor, Vladimir Laletin, Cathy Costa Da Silva, Armelle Goubard, Emmanuelle Josselin, Remy Castellano, Adrien Krug, Julien Vernerey, Raynier Devillier, Daniel Olive, Els Verhoeyen, Eric Vivier, Nicholas D. Huntington, Jacques Nunes, Geoffrey Guittard
Summary: This study investigates the impact of targeting an inhibiting protein called CISH in natural killer (NK) cells on their functions and antitumor properties. The results show that CISH deletion enhances NK cell activation and killing abilities, while limiting NK cell exhaustion. Furthermore, CISH deletion optimizes NK cell accumulation in tumors and improves the effectiveness of antitumor responses. Therefore, CISH has been validated as a potential therapeutic target to enhance NK cell immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, Research & Experimental
Gabriella Leung, Yuhuan Zhou, Philip Ostrowski, Sivakami Mylvaganam, Parastoo Boroumand, Daniel J. Mulder, Conghui Guo, Aleixo M. Muise, Spencer A. Freeman
Summary: The deficiency of ARPC1B can disrupt the nucleation of ARP2/3 complexes by WASP, affecting the cytoskeletal structures in B cells and macrophages, leading to increased tonic signaling in immune cells and impacting the threshold for activation in response to microbial-associated molecular patterns. This highlights the critical role of ARPC1B in controlling steady-state signaling of immune cells.
Article
Oncology
Cristina Travelli, Giorgia Colombo, Martina Aliotta, Francesca Fagiani, Natalia Fava, Rita De Sanctis, Ambra A. Grolla, Joe G. N. Garcia, Nausicaa Clemente, Paola Portararo, Massimo Costanza, Fabrizio Condorelli, Mario Paolo Colombo, Sabina Sangaletti, Armando A. Genazzani
Summary: Neutralization of eNAMPT with a specific antibody leads to decreased tumor size and reduced number of lung metastases. The study reveals that eNAMPT controls T-cell response through the PD-L1/PD-1 axis, and neutralization of eNAMPT restores antitumoral immune responses by activating CD8+IFN gamma+GrzB+ T cells and reducing the immunosuppressive phenotype of T regulatory cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Wenyi Qin, Xiaofeng Rong, Chao Yu, Ping Jia, Juan Yang, Guoqing Zhou
Summary: This study found that the SLAMF8 gene is aberrantly expressed in rheumatoid arthritis (RA) patients and plays an important role in initiating inflammation and maintaining a pro-inflammatory environment. Targeted inhibition of SLAMF8 can attenuate the severity of RA by blocking the TLR4/NF-kappa B signaling pathway. This research provides a new potential target for the treatment of RA.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Cell Biology
Weili Xu, Tessa Bergsbaken, Karen L. Edelblum
Summary: Intestinal tissue-resident lymphocytes play a critical role in maintaining the mucosal barrier and preventing enteric infections. CD103, an integrin expressed on these lymphocytes, is involved in their activation and function, but the molecular signals it triggers are still not well understood. Research in this field can provide insights into the functional contribution of CD103 and its potential as a therapeutic target for tissue-resident lymphocyte-related diseases.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2022)
Article
Oncology
Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston, Nigel J. Waterhouse, Amanda C. Stanley, Lucie Leveque-El Mouttie, Grace M. Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P. Brown, David Goldstein
Summary: This study evaluated the safety, efficacy, and pharmacodynamics of pixatimod and nivolumab in immunologically cold cancers. The combination therapy showed some antitumor activity in the MSS mCRC cohort, indicating the need for further investigation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Apple Hui Min Tay, Ruben Prieto-Diaz, Shiyong Neo, Le Tong, Xinsong Chen, Valentina Carannante, Bjorn Onfelt, Johan Hartman, Felix Haglund, Maria Majellaro, Jhonny Azuaje, Xerardo Garcia-Mera, Jose M. Brea, Maria Loza, Willem Jespers, Hugo Gutierrez-de-Teran, Eddy Sotelo, Andreas Lundqvist
Summary: This study synthesized five potent A(2B)AR antagonists and a dual A(2A)AR/A(2B)AR antagonist, and evaluated their therapeutic potential in cancer immunotherapy. The results showed that A(2B)AR antagonists can enhance T and NK cell proliferation, increase cytokine production, and boost lymphocyte infiltration into tumor spheroids without altering adhesion molecule expression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Sean Hammond, Anna Olsson-Brown, Joshua Gardner, Paul Thomson, Serat-E Ali, Carol Jolly, Dan Carr, Lorenzo Ressel, Munir Pirmohamed, Dean Naisbitt
Summary: This study presented a case of a patient who developed immune-related adverse reactions after receiving ICI treatment, with experimental confirmation of the potential interactions between ICIs and other medications. It underscores the importance of considering all concomitant medications in patients receiving ICIs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Camila Marques-da-Silva, Kristen Peissig, Michael P. Walker, Justine Shiau, Carson Bowers, Dennis E. Kyle, Rahul Vijay, Scott E. Lindner, Samarchith P. Kurup
Summary: Malaria is a devastating disease affecting more than half of the global population. Research has shown that direct type I interferon signaling in infected hepatocytes is necessary for controlling malaria, and it has also been discovered that the majority of infected hepatocytes naturally eliminate the parasite, suggesting the existence of cell-autonomous immune responses. These findings challenge existing paradigms in malaria immunobiology and have the potential to inspire new anti-malaria drugs and vaccine strategies.
Article
Oncology
Meenal Sinha, Courtney Betts, Li Zhang, Madeline J. Griffith, Isabelle Solman, Brandon Chen, Eric Liu, Whitney Tamaki, Jacob Stultz, Jaqueline Marquez, Shamilene Sivagnanam, Alexander Cheung, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Matthew Crocker, Kendra Todd, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Charles D. Lopez, Margaret Tempero, Lisa M. Coussens, Lawrence Fong
Summary: In preclinical studies, ibrutinib improved the antitumor efficacy of chemotherapy for PDAC. A phase 1b clinical trial was conducted to determine the safety, tolerability, and immunologic effects of ibrutinib treatment in advanced PDAC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Sylvain Raimbault, Guillaume Monneret, Morgane Gossez, Fabienne Venet, Alexandre Belot, Franck Zekre, Solene Remy, Etienne Javouhey
Summary: In this study, the researchers examined the use of monocyte human leucocyte antigen (mHLA)-DR as a potential diagnostic marker for secondary HLH (sHLH). They found that levels of mHLA-DR were significantly higher in patients with sHLH compared to healthy children and those with septic shock. Additionally, mHLA-DR levels decreased after treatment initiation. The findings suggest that elevated mHLA-DR could aid in the diagnosis of sHLH and distinguish it from septic shock.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Genetics & Heredity
Ivona Aksentijevich
Summary: Immune responses require a delicate balance - too weak or too strong a response can cause issues. Spleen tyrosine kinase plays a crucial role in multiple signaling pathways, and its gain-of-function alterations can lead to various problems, including hypogammaglobulinemia and predisposition to B cell lymphoma.
